• Why We Need Clinical Trials For Lymphoma
  • Hodgkin’s Lymphoma: The ‘Good’ Cancer?
  • At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report
  • Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients
  • Duvelisib Safe, Effective in Refractory Non-Hodgkin’s Lymphoma Patients, DYNAMO Study Shows
  • Adcetris-Gemzar Combo Yields High Complete Response Rates in Young Hodgkin’s Lymphoma Patients, Study Finds
  • FDA to Begin Reviewing Vyxeos as Treatment for Acute Myeloid Leukemia
  • Be Kind to Yourself when You’re in Pain
  • 37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear
  • 3D Signatures Advances Telo-HL Test to Determine Relapse Risk in Hodgkin’s Lymphoma Patients
  • Adcetris Shows Promise in Phase 3 Trial to Treat Certain Cutaneous T-Cell Lymphoma Patients
  • Imbruvica Seen to Improve Long-Term Survival in Certain Leukemia Patients, Trial Data Show
  • Community Oncologists Present 40 Abstracts on New Cancer Research at ASCO 2017